In situ quantification of aberrant p53 in colorectal neoplasia

References

• ADAMS, E. J., GREEN, J. A., CLARK, A. H. and YOUNGSON, J. H. 1999, Comparison of different scoring systems for immunohistochemical staining. Journal of Clinical Pathology, 52 (1), 75-77. AMERICAN SOCIETY OF CLINICAL ONCOLOGY 1996, Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Journal of Clinical Oncology, 14 (10), 2843–2877.
   Google Scholar
• BS, I. O., MuLDER, J.-W. R, OFFERHAUS, G. J. A., VOGELSTEIN, B. and HAMILTON, S. R 1994, An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. Journal of Pathology, 172, 5–12.
   Google Scholar
• BONSING, B. A., CORVER, W. E., GORSIRA, M. C. B., vAN VLIET, M., OUD, P. S., CORNELISSE, C. J. and FLEUREN, G. 1997, Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytome-try. Cytometry, 28, 11–24.
   Google Scholar
• CAMPO, E., DE LA CALLE-MARTIN, O., MIQUEL, R, PALACIN, A., ROMERO, M., FABREGAT, V, VIVES, J., CARDESA, A. and YAGUE, J. 1991, Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Research, 51, 4436–4442.
   Google Scholar
• CARON DE FROMENTAL, C. and Soussi, T. 1992, TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes, Chromosomes and Cancer, 4 (1), 1–15.
   PubMed Web of Science ®Google Scholar
• CHIN, KHEW-VOON, KAZTJMITSTJ, VEDA, PDSTAN, IRA and GOTTESMAN, MICHAEL M. 1992, Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science, 255, 459–462.
   PubMed Web of Science ®Google Scholar
• COHEN, J. 1960, A coefficient of agreement for nominal scales. Educational and Psychological Measurement, 20, 37–46.
   Web of Science ®Google Scholar
• COHEN, A. M., MINSKY, B. D. and SCHILSKY, R 1993, Colon cancer. In Cancer: Principles and Practice of Oncology, edited by V. T. Devita, S. Hellman and S. Rosenberg, 4th edition (Philadelphia: J. B. Lippincott), pp. 929–977.
   Google Scholar
• CUNNINGHAM, J., LUST, J. A., SCHALD, D., BREN, G. D., CARPENTER, H. A., RISSA, E., KOVACH, J. S. and THIBODEAU, S. A. 1992, Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Research, 52, 1974–1980.
   PubMed Web of Science ®Google Scholar
• DOWELL, S. P. and HALL, P. A. 1995, The p53 tumor suppressor gene and tumor prognosis: is there a relationship? Journal of Pathology, 177, 221–224.
   Google Scholar
• EL-DIERY, W. S. 1998, Regulation of p53 downstream genes. Seminars in Cancer Biology, 8, 345-357. FEARON, E. R and VOGELSTEIN, B. 1990, A genetic model for colorectal tumorigenesis. Cell, 61, 759–767.
   Google Scholar
• FEARON, E. R. and JONES, P. A. 1992, Progressing toward a molecular description of colorectal cancer development. FASEB Journal, 6, 2783–2790.
   PubMed Web of Science ®Google Scholar
• FIDLER, I. 1997, Molecular biology of cancer invasion and metastasis. In Cancer: Principles and Practice of Oncology, edited by V. T. Devita, S. Hellman and S. Rosenberg, 5th edition (Philadelphia: Lippincott-Raven), pp. 135–152.
   Google Scholar
• FISHER, C. J., Gui vi-r, C. E., VorrEEK, B., BARNES, D. M. and MILLIS, R R. 1994, Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. British Journal of Cancer, 69, 26–31.
   Google Scholar
• GALEN, R. S. and GAMBINO, S. R. 1975, Beyond Normality: The Predictive Value and Efficiency of Medical Diagnoses (New York: Wiley & Sons).
   Google Scholar
• GANNON, J. V, IGGO, R. and LANE, D. P. 1990, Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO Journal, 9 (5), 1595–1602.
   PubMed Web of Science ®Google Scholar
• GRAEBER, T. G., OSMANIAN, C., JACKS, T, HOUSMAN, D. E., KocH, C. J., LowE, S. W. and GIACCIA, A. J. 1996, Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 379, 88–91.
   PubMed Web of Science ®Google Scholar
• GRECO, C., GANDOLFO, G. M., MATTEL F., GRADILONE, A., SILVANA, A., PASTORE, L. I., CASALE, V., CASOLE, P., GRASSI, A., CIANCIULLI, A. M. and AGLIANO, A. M. 1994, Detection of c-myb genetic alterations and mutant p53 serum protein in patients with benign and malignant colon lesions. Anticancer Research, 14, 1433–1440.
   Google Scholar
• HARRIS, L. C., REMACK, J. S., HOUGHTON, P. J. and BRENT, T. P. 1996, Wild-type p53 suppresses transcription of the human 06-methylguanine-DNA methyltransferase gene. Cancer Research, 56, 2029–2032.
   PubMed Web of Science ®Google Scholar
• HENDRIX, M. J. 2000, De-mystifying the mechanism(s) of maspin. Nature Medicine, 6, 374-376. HUNTER, T. 2000, Signaling - 2000 and beyond. Cell, 100, 113–127.
   PubMed Web of Science ®Google Scholar
• JOYPAUL, B. V, VarrEsEK, B., NEWMAN, L., HOPWOOD, D., GRANT, A., LANE, D. P. and CUSCHIERI, A. 1993, Enzyme-linked immunosorbent assay for p53 in gastrointestinal malignancy: comparison with immunohistochemistry. Histopathology, 23, 465–470.
   PubMed Web of Science ®Google Scholar
• KELSEY, J. L., THOMPSON, W. D. and EVANS, A. S. (editors) 1986, Methods in Observational Epidemiology (New York: Oxford University Press).
   Google Scholar
• KEME, C. J., DONEHOWER, L A., BRADLEY, A. and BALmAIN, A. 1993, Reduction of p53 gene dosage does not increase initiation of promotion but enhances malignant progression of chemically induced skin tumors. Cell, 74, 813–822.
   PubMed Web of Science ®Google Scholar
• KIMURA, O., SUGAMURA, T., KIJIMA, M., MAKIN°, H., SHIRAI, S., TATEBE, H., ITO, H. and KAIBARA, N. 1996, Flow cytometric examination of p53 protein in primary tumors and metastases to the liver and lymph nodes of colorectal cancer. Diseases of the Colon and Rectum, 39 (12), 1428–1433.
   Google Scholar
• KRAISS, S., SPIESS, S., REIHSAUS, E. and MONTENARH, M. 1991, Correlation of metabolic stability and altered quaternary structure of oncoprotein p53 with cell transformation. Experimental Cell Research, 192, 157–164.
   PubMed Web of Science ®Google Scholar
• LANE, D. and HALL, P. 1997, MDM2 - arbiter of p53's destruction. Trends in Biochemical Sciences, 10, 371–410.
   Google Scholar
• LEV, R (editor) 1990, Adenomatous Polyps of the Colon (New York: Springer-Verlag).
   Google Scholar
• LEVINE, A. J. and MOMAND, J. 1990, Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products. Biochimica et Biophysica Acta, 1032, 119–136.
   PubMed Web of Science ®Google Scholar
• LEVINE, A. J., PERRY, M. E., CHANG, A., SILVER, A., DITTMER, D., Wu, M. and WELSH, D. 1994, The role of the p53 tumor suppressor gene in tumorigenesis. British Journal of Cancer, 69, 409–416.
   PubMed Web of Science ®Google Scholar
• LOWE, S. W, JACKS, T., HOUSMAN, D. E. and RULEY, H. E. 1994, Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proceedings of the National Academy of Sciences USA, 91, 2026–2030.
   PubMed Web of Science ®Google Scholar
• LUC., J.-C., NEUGUT, A. I., GARBOWSKI, G., FoRDE, K, TREAT, M., Smrru, S., CARNEY, W. and BRANDT-RAUF, P. 1995, Levels of p53 antigen in the plasma of patients with adenomas and adenocarcinomas of the colon. Cancer Letters, 91 (2), 235–240.
   PubMed Web of Science ®Google Scholar
• MCSHANE, L. M., AAMODT, R., CORDON-CARDO, C., COTE, R., FARAGGI, D., FRADET, Y, GROSSMAN, H. B., PENG, A., TAUBE, S. E. and WALDMAN, F. M. 2000, Reproducibility of p53 immunohistochemistry in bladder tumors. Clinical Cancer Research, 6 (5), 1854–1864.
   Google Scholar
• MORIN, P. J., SPARKS, A. B., KORINEK, V, BARKER, N., CI-EVERS, H., VOGELSTEIN, B. and KINZLER, K. W. 1997, Activation of fl-catenin/Tcf signaling in colon cancer by mutations in fl-catenin or APC. Science, 275, 1787–1790.
   Google Scholar
• O'LEARY, T. and CALVIN, V. 1998, U.S. Food and Drug Administration (FDA) approval of HERCEPTEST assay (HER-2). Joint Meeting of the 'Hematology and Pathology Devices' and 'Immunology Devices' Panels. http://www.fda.gov/, click on Transcript: Part 2 pages 1–113).
   Google Scholar
• OZBUN, M. A. and BUTEL, J. S. 1997, p53 tumor suppressor gene: structure and function. In Encyclopedia of Cancer, Vol. II, edited by J. R. Bertino (New York: Academic Press), pp. 1240–1257.
   Google Scholar
• RIES, L. A. Cr., KOSARY, C. L., HANKEY, B. E, MILLER, B. A., CI-EGG, L. and EDWARDS, B. K. (editors) 1999, SEER Cancer Statistics Review, 1973–1998 (Bethesda: Cancer Statistics Branch, Cancer Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute).
   Google Scholar
• ROSANFI i I, G. P., WIRNSBERGER, G. H., PURSTNER, P., ET AL. 1993, DNA flow cytometry and immunohistochemical demonstration of mutant p53 protein versus TPs and mutant p53 protein serum levels in human breast cancer. Proceedings of the American Association for Cancer Research, 34, A1353.
   Google Scholar
• RUDDON, R. W. (editor) 1987, Cancer Biology (New York: Oxford University Press).
   Google Scholar
• ScuurrENEEED, D. and WINAWER, S. J. 1982, Cancer epidemiology and prevention. In Cancer Epidemiology, edited by D. Schottenfeld and D. Fraumeni (Philadelphia: Saunders).
   Google Scholar
• SHARMA, S., SCHWARTE-WALDHOFF, I., OBERHUBER, H. and SCHAFER, R. 1993, Functional interaction of wild-type and mutant p53 transfected into human tumor cell lines carrying activated RAS genes. Cell Growth and Differentiation, 4, 861–869.
   PubMedGoogle Scholar
• SLUM, K-S., Kirvi, K-H., PARK, B.-W, LEE, S.-Y, CHoi, J.-H., AN, W.-D. and PARK, E.-B. 1998, Increased serum levels of mutant p53 proteins in patients with colorectal cancer. Journal of the Korean Medical Society, 13, 44–48.
   Google Scholar
• SHIN, D. M., Kim, J., Ro, J. Y, HryrnEmAN, J., Rom, J. A., HONG, W. K. and HiliELMAN, W. N. 1994, Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Research, 54, 321–326.
   PubMed Web of Science ®Google Scholar
• SORY, A., MINAMOTO, T., OHTA, K, YAMASHITA, K, SAWAGTJCHI, M., MAT, M. and MISIUNA, P. 1997, Does p53 overexpression cause metastases in early invasive colorectal adenocarcinoma? European Journal of Surgery, 163 (9), 685–692.
   Google Scholar
• SOUSSI, T, LEGROS, Y, LUBIN, R., ORY, K and ScHucirrHoLz, B. 1994, Multifactorial analysis of p53 alteration in human cancer: a review. International Journal of Cancer, 57, 1–9.
   Google Scholar
• SYMONDS, H., KRALL, L., REMINGTON, L., SAENZ, ROBLES M., JACKS, T. and VAN DYKET, T. 1994, p53-dependent aptosis in vivo: impact of p53 inactivation on tumorigenesis. Cold Spring Harbor Symposium on Quantative Biology, 59, 247–257.
   PubMedGoogle Scholar
• THOMIINSON, R. H. and GRAY, L. H. 1955, The histological structure of some human lung cancers and the possible implications for radiotherapy. British Journal of Cancer, 9, 539–549.
   PubMed Web of Science ®Google Scholar
• TOMINAGA, O., HAMELIN, R., REMVIKOS, Y, SAIMAON, R. and THOMAS, G. 1992, p53 from basic research to clinical applications. Critical Reviews in Oncogenesis, 3, 257–282.
   PubMedGoogle Scholar
• VAN DER KOOY, K., RooKus, M. A., PETERSE, H. L. and LEEUWEN, F. E. 1996, p53 overexpression in relation to risk factors for breast cancer. American Journal of Epidemiology, 144 (10), 924–933.
   PubMed Web of Science ®Google Scholar
• VAUPEL, P. W. and HOCKEL, M. 1995, Oxygenation status of human tumors; a reappraisal using computerised p02 histography. In Tumor Oxygenation, edited by P. W. Vaupel, D. K. Kelleher and M. Gunderoth (Stuttgart: Gustav Fischer), pp. 219–232.
   Google Scholar
• VOGELSTEIN, B., FEARON, E. R., HAMILTON, S. R., KERN, S. E., PRESINGER, A. C., LEPPERT, M., NAKAMURA, Y, Wirrrn, R., Smrr, A. M. and Bos, J. L. 1988, Genetic alterations during colorectal tumor development. New England Journal of Medicine, 319 (9), 525–532.
   PubMed Web of Science ®Google Scholar
• VOGEISTEIN, B., LANE, D. and LEVINE, A. J. 2000, Surfing the p53 network. Nature, 408 (16), 307–310.
   PubMed Web of Science ®Google Scholar
• VOJTESEK, B., DOLEZALOVA, H., LAUEROVA, L., SVITAKOVA, M., HAVIIS, P., KOVARIK, J., MIDGLEY, C. A. and LANE, D. P. 1995, Conformational changes in p53 analyzed, using new antibodies to the core DNA binding domain of the protein. Oncogene, 10, 389–393.
   PubMed Web of Science ®Google Scholar